Advertisement
GH or MTD or NTRA
Which Stock Would AI Choose? Guardant Health (GH) vs. Mettler-Toledo International (MTD) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Guardant Health (GH) reported strong second-quarter 2026 revenue growth of 44% and raised full-year guidance, driving notable recent price appreciation.
- Mettler-Toledo International (MTD) delivered in-line quarterly results with an earnings beat and modest revenue growth, reflecting steady performance in its precision instruments segment.
- Natera (NTRA) maintains momentum in its cell-free DNA testing franchise ahead of its upcoming quarterly report, with year-to-date gains supporting relative stability.
- The three stocks span distinct sectors—oncology diagnostics for GH and NTRA versus life sciences tools for MTD—creating varied exposure to healthcare innovation cycles and end-market demand.
- Recent market activity highlights contrasts in growth velocity, with GH showing the most pronounced short-term momentum amid positive catalysts.
- Valuation sensitivity differs, as higher-growth names like GH and NTRA trade with greater responsiveness to clinical and reimbursement developments compared to MTD’s more mature profile.
Introduction
This comparison examines Guardant Health (GH), Mettler-Toledo International (MTD), and Natera (NTRA), three publicly traded companies operating in precision medicine and laboratory instrumentation. The analysis focuses on recent performance trends, business fundamentals, and market positioning to assist traders and investors evaluating relative opportunities within the healthcare sector. Participants seeking exposure to oncology diagnostics, genetic testing, or analytical instruments may find the side-by-side assessment useful for portfolio allocation decisions in the current environment.
GH Overview and Recent Performance
Guardant Health (GH) develops liquid biopsy tests for oncology applications, including screening and treatment monitoring. In recent weeks, the company reported second-quarter 2026 revenue of $335 million, representing 44% year-over-year growth driven by oncology and screening segments. Management raised full-year revenue guidance to a range of $1.34 billion to $1.36 billion. The stock price responded positively to these results, closing near $162 on July 31, 2026, after notable gains in recent market activity. Sentiment has been supported by expanding test volumes, new coverage decisions, and clinical guideline inclusions that bolster adoption prospects.
MTD Overview and Recent Performance
Mettler-Toledo International (MTD) provides precision instruments and services for laboratory and industrial applications. During the most recent quarter, the company posted revenue of $1.03 billion, in line with expectations and up modestly year over year. Adjusted earnings per share exceeded consensus estimates, prompting a slight upward revision to full-year guidance. As of July 31, 2026, shares traded near $1,416. Recent performance has been relatively stable, with year-to-date returns in the low single digits amid broader market conditions. Sentiment reflects consistent demand for its measurement solutions across life sciences and manufacturing end markets.
NTRA Overview and Recent Performance
Natera (NTRA) specializes in cell-free DNA testing for oncology, prenatal, and organ health applications. The company is scheduled to report second-quarter 2026 results on August 6. As of July 31, 2026, the stock closed near $268, reflecting year-to-date gains of approximately 10% and proximity to its 52-week high. Recent market activity has been influenced by ongoing volume growth in its Signatera minimal residual disease test and broader adoption of precision medicine solutions. Sentiment remains constructive ahead of the earnings release, supported by the company’s established position in genetic testing.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics. Only those demonstrating the strongest alignment with prevailing market conditions receive placement in the trending section. Available bots exhibit a wide range of historical returns, win rates, and drawdown profiles, allowing users to identify options suited to specific risk tolerances and trading styles. Review the curated list to explore current opportunities.
Head-to-Head Comparison
Guardant Health (GH) and Natera (NTRA) operate in oncology-focused diagnostics with high revenue growth potential tied to clinical adoption and reimbursement, whereas Mettler-Toledo International (MTD) generates more predictable revenue from precision instruments serving diversified laboratory and industrial customers. Recent momentum has favored GH following its earnings beat and guidance raise, while MTD has shown steadier but lower-volatility movement. NTRA offers a balance through its broader testing portfolio. Risk factors include regulatory and reimbursement uncertainties for the diagnostics names versus cyclical exposure for MTD. Valuation multiples for GH and NTRA tend to embed stronger growth assumptions, creating greater sensitivity to news flow compared with MTD’s more mature earnings profile. Sector positioning places the former two in high-growth healthcare innovation and the latter in essential tools and services.
Tickeron AI Verdict
Based on observable trend consistency, relative stability, and catalyst profiles, Tickeron’s AI-driven analysis would likely favor Natera (NTRA) in the current environment, though with important caveats. Natera (NTRA) offers a more balanced risk-reward profile through demonstrated volume momentum and a diversified revenue base. Guardant Health (GH) presents higher-beta opportunities during periods of strong growth acceleration, while Mettler-Toledo International (MTD) provides defensive characteristics. The verdict leans toward Natera (NTRA) for stability-oriented positioning while acknowledging that market conditions could shift preferences toward other names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 0 FA rating(s) are green whileMTD’s FA Score has 2 green FA rating(s), and NTRA’s FA Score reflects 1 green FA rating(s).
- GH’s FA Score: 0 green, 5 red.
- MTD’s FA Score: 2 green, 3 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 5 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s), and NTRA’s TA Score reflects 3 bullish TA indicator(s).
- GH’s TA Score: 5 bullish, 3 bearish.
- MTD’s TA Score: 4 bullish, 4 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
GH (@Medical Specialties) experienced а +4.01% price change this week, while MTD (@Medical Specialties) price change was +0.93% , and NTRA (@Medical Specialties) price fluctuated +20.29% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
Reported Earning Dates
GH is expected to report earnings on Oct 29, 2026.
MTD is expected to report earnings on Nov 05, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| GH | MTD | NTRA | |
| Capitalization | 22.6B | 28.6B | 46.4B |
| EBITDA | -411.19M | 1.3B | -227.7M |
| Gain YTD | 54.278 | 1.940 | 40.600 |
| P/E Ratio | N/A | 32.22 | N/A |
| Revenue | 1.18B | 4.13B | 2.5B |
| Total Cash | 1.05B | 51.4M | 1.09B |
| Total Debt | 1.7B | 2.11B | 240M |
GH | MTD | NTRA | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 82 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 99 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 77 | 100 | 22 | |
SMR RATING 1..100 | 100 | 2 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | 19 | 39 | |
P/E GROWTH RATING 1..100 | 100 | 49 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (49) in the Biotechnology industry is in the same range as GH (65) in the Medical Or Nursing Services industry, and is somewhat better than the same rating for MTD (99) in the Medical Specialties industry. This means that NTRA's stock grew similarly to GH’s and somewhat faster than MTD’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is somewhat better than the same rating for GH (77) in the Medical Or Nursing Services industry, and is significantly better than the same rating for MTD (100) in the Medical Specialties industry. This means that NTRA's stock grew somewhat faster than GH’s and significantly faster than MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for NTRA (96) in the Biotechnology industry, and is significantly better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that MTD's stock grew significantly faster than NTRA’s and significantly faster than GH’s over the last 12 months.
MTD's Price Growth Rating (19) in the Medical Specialties industry is in the same range as GH (35) in the Medical Or Nursing Services industry, and is in the same range as NTRA (39) in the Biotechnology industry. This means that MTD's stock grew similarly to GH’s and similarly to NTRA’s over the last 12 months.
MTD's P/E Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for GH (100) in the Medical Or Nursing Services industry, and is somewhat better than the same rating for NTRA (100) in the Biotechnology industry. This means that MTD's stock grew somewhat faster than GH’s and somewhat faster than NTRA’s over the last 12 months.
| GH | MTD | NTRA | |
|---|---|---|---|
| RSI ODDS (%) | 4 days ago 73% | 2 days ago 87% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 60% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 70% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 60% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 61% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 59% | 2 days ago 81% |
| Advances ODDS (%) | 4 days ago 82% | 6 days ago 60% | 5 days ago 80% |
| Declines ODDS (%) | 12 days ago 85% | 4 days ago 65% | 3 days ago 77% |
| BollingerBands ODDS (%) | 6 days ago 69% | 2 days ago 81% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 59% | 2 days ago 83% |
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -0.02% | ||
| A - MTD | 70% Closely correlated | +0.16% | ||
| BRKR - MTD | 67% Closely correlated | -2.29% | ||
| TMO - MTD | 66% Closely correlated | +0.38% | ||
| AZTA - MTD | 61% Loosely correlated | -3.39% | ||
| RVTY - MTD | 59% Loosely correlated | -0.68% | ||
More | ||||